The Experts below are selected from a list of 4365 Experts worldwide ranked by ideXlab platform

Ikkyung Jang - One of the best experts on this subject based on the ideXlab platform.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

Shuo Zhang - One of the best experts on this subject based on the ideXlab platform.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Haibo Jia, Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Jingbo Hou, Huimin Liu, Haixia Liu, Shuo Zhang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm(2) and 0.4 μg/mm(2), respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

Willem J. Giessen - One of the best experts on this subject based on the ideXlab platform.

  • the genous endothelial progenitor cell capture Stent accelerates Stent re endothelialization but does not affect intimal hyperplasia in porcine coronary arteries
    Catheterization and Cardiovascular Interventions, 2012
    Co-Authors: Heleen M M Van Beusekom, Oana Sorop, Gökhan Ertaş, Willem J. Giessen
    Abstract:

    Objectives: To study the effect of endothelial progenitor cell (EPC) capture on the vascular response to coronary Stenting. Background: The introduction of drug-eluting Stents has reduced the need for target lesion revascularization, but their effect on delayed healing, inflammation, and vascular dysfunction has emphasized the need to design strategies that improve current DES. One such strategy is to improve endothelialization by capturing CD34-positive cells (EPC) by the Stent Surface. The first human clinical trial using coronary EPC capture Stents showed Stent safety but neointimal thickness (NIT) was not reduced compared to bare metal Stents (BMS). To understand these responses we studied the coronary response to the EPC capture Stent in swine. Methods and Results: The Stent, coated with murine antihuman monoclonal CD34 antibodies, was assessed with QCA guided Stent implantation in normal swine coronary arteries for early endothelialization at 2 and 5 days, and NIT at 28 and 90 days in comparison to control Stents carrying a non-specific murine antibody or to BMS. The main finding was that while the EPC capture Stent significantly improved early endothelialization it did not reduce NIT at 28 and 90 days. Conclusions: The EPC capture Stent improves early endothelialization in swine but this does not affect neointimal thickness as compared to control Stents at 28 and 90 days. © 2011 Wiley Periodicals, Inc.

  • the genous endothelial progenitor cell capture Stent accelerates Stent re endothelialization but does not affect intimal hyperplasia in porcine coronary arteries
    Catheterization and Cardiovascular Interventions, 2012
    Co-Authors: Heleen M M Van Beusekom, Oana Sorop, Gökhan Ertaş, Willem J. Giessen
    Abstract:

    OBJECTIVES: To study the effect of endothelial progenitor cell (EPC) capture on the vascular response to coronary Stenting. BACKGROUND: The introduction of drug-eluting Stents has reduced the need for target lesion revascularization, but their effect on delayed healing, inflammation, and vascular dysfunction has emphasized the need to design strategies that improve current DES. One such strategy is to improve endothelialization by capturing CD34-positive cells (EPC) by the Stent Surface. The first human clinical trial using coronary EPC capture Stents showed Stent safety but neointimal thickness (NIT) was not reduced compared to bare metal Stents (BMS). To understand these responses we studied the coronary response to the EPC capture Stent in swine. METHODS AND RESULTS: The Stent, coated with murine antihuman monoclonal CD34 antibodies, was assessed with QCA guided Stent implantation in normal swine coronary arteries for early endothelialization at 2 and 5 days, and NIT at 28 and 90 days in comparison to control Stents carrying a non-specific murine antibody or to BMS. The main finding was that while the EPC capture Stent significantly improved early endothelialization it did not reduce NIT at 28 and 90 days. CONCLUSIONS: The EPC capture Stent improves early endothelialization in swine but this does not affect neointimal thickness as compared to control Stents at 28 and 90 days.

Junying Kong - One of the best experts on this subject based on the ideXlab platform.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Haibo Jia, Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Jingbo Hou, Huimin Liu, Haixia Liu, Shuo Zhang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm(2) and 0.4 μg/mm(2), respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

Maomao Zhang - One of the best experts on this subject based on the ideXlab platform.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Haibo Jia, Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Jingbo Hou, Huimin Liu, Haixia Liu, Shuo Zhang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm(2) and 0.4 μg/mm(2), respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES.

  • a novel polymer free paclitaxel eluting Stent with a nanoporous Surface for rapid endothelialization and inhibition of intimal hyperplasia comparison with a polymer based sirolimus eluting Stent and bare metal Stent in a porcine model
    Journal of Biomedical Materials Research Part A, 2011
    Co-Authors: Junying Kong, Xingtao Huang, Shaosong Zhang, Jinwei Tian, Maomao Zhang, Sining Hu, Bo Yu, Jian Wu, Shuo Zhang, Ikkyung Jang
    Abstract:

    Hypersensitivity and inflammatory responses to polymers may be responsible for late Stent thrombosis after implantation of a drug-eluting Stent (DES). Polymer-free DES may reduce the prevalence of these adverse reactions in vessels. We evaluated a polymer-free paclitaxel-eluting-Stent with a nanoporous Surface (nano-PES) for endothelialization and inhibition of neointimal hyperplasia by optical coherence tomography (OCT) and pathology in a porcine model. Nano-PES with high-dose (HD) and low-dose (LD) paclitaxel (1.0 μg/mm2 and 0.4 μg/mm2, respectively) was compared with a sirolimus-eluting Stent (SES) and bare-metal Stent (BMS) in a porcine model. Fifty-three Stents (14 HD, 14 LD, 14 SES, 11 BMS) were implanted in 18 minipigs. At 14 days, nano-PES with HD and LD showed more complete endothelialization compared with SES. BMS had 100% endothelial coverage. At 28 days, a significant reduction in neointimal hyperplasia was detected by OCT in the nano-PES HD group compared with BMS. No benefit in prevention of the neointimal hyperplasia was observed in the nano-PES LD group. Nano-PES Stents showed decreased deposition of fibrin and inflammation compared with SES. Pharmacokinetic studies revealed that nano-PES could effectively deliver the drug to the local coronary artery and it released the drug more rapidly than SES. Such a release profile was favorable for rapid endothelialization of nano-PES. The present study showed the nano-PES to be a new drug-delivery technology; that it used a nanoporous Stent Surface; that it offered desirable drug-elution properties without the use of polymers; that it may translate into an improved safety profile for next-generation DES. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.